Q-omics provides the consensus-scored SOX7 profile across patient tissues and cancer cell-line models. SOX7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SOX7 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, SOX7 RNA expression shows 17,548 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where SOX7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX7 survival associations across molecular data types. SOX7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX7 RNA expression–survival associations across cancer types. High SOX7 expression shows unfavorable associations in KIRP, MESO, STAD, COAD and THCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SOX7 RNA expression.
This table summarizes SOX7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SOX7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX7 shows lower tumor expression in LUAD, KICH, KIRP, THCA, LUSC and UCEC. The LUAD box plot shows higher SOX7 RNA expression in normal versus tumor tissue (log2 FC = −2.706, t-test p < 0.001).
This table shows molecular features associated with SOX7 in patient tissues and cancer cell lines. In patient samples, SOX7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
